Abiopharma

News list

Lisle Shawn G 🟢 acquired 10.1K shares (3 derivative) of STEPAN CO (SCL) at $50.55 Transaction Date: Aug 26, 2025 | Filing ID: 021003

Full text

News bot Aug. 27, 2025, 9:22 p.m.
🔍 Lisle Shawn G (Executive)

Company: STEPAN CO (SCL)

Report Date: 2025-08-26
Transaction Summary:
- Total transactions: 3
- Derivative instruments: 3
- Holdings reported: 0
- Total shares acquired: 10,054
Detailed Transactions and Holdings:
- Acquired 3,462 shares of Restricted Stock Units (Derivative)
  Date: 2025-08-26 | Code: A | Expires: 2028-08-26 | Exercise: 2026-08-26 | equity_swap_involved: 0 | shares_owned_after: 3,462.00 | transaction_form_type: 4 | Footnotes: F1, F2
- Acquired 1,731 shares of Performance Shares (Derivative)
  Date: 2025-08-26 | Code: A | equity_swap_involved: 0 | shares_owned_after: 1,731.00 | transaction_form_type: 4 | Footnotes: F3, F4, F4
- Acquired 4,861 shares of Stock Appreciation Right at $50.55 per share (Derivative)
  Date: 2025-08-26 | Code: A | Expires: 2035-08-26 | Exercise: 2026-08-26 | equity_swap_involved: 0 | shares_owned_after: 4,861.00 | transaction_form_type: 4 | Footnotes: F2
Footnotes:
- F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Stepan Company common stock.
- F2: Vest ratably over three years beginning on the date shown.
- F3: Each performance share represents a contingent right to receive one share of Stepan Company common stock.
- F4: The performance shares vest upon the certification of Stepan Company achieving certain performance goals for the performance period ending December 31, 2027.